MIRANasdaqPharmaceutical Preparations

MIRA PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.64+0.01 (+1.55%)

Close on Oct 19, 2026

Market cap: $26.98M
P/E (TTM): –
Dividend yield: –

MIRA PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31
Research & Development	0.71	0.52	0.50	0.41	0.50	0.31	0.86	1.07	0.61	0.76	0.39	1.02	-0.10	0.27	0.88	0.71	–	–
General & Administrative	0.45	0.58	5.33	0.90	1.05	1.49	1.58	1.01	1.12	1.01	2.67	2.14	1.07	0.61	0.05	0.74	1.59	–
Operating Expenses	1.16	1.10	5.82	1.32	1.55	1.81	2.44	2.08	1.73	1.77	3.06	3.16	0.97	1.34	1.35	1.81	2.42	–
Interest Expense	–	–	–	–	–	-0.02	-0.04	-0.04	-0.04	-0.05	2.73	0.43	0.30	0.00	0.00	0.00	0.00	–
Other Non-Operating Income	-0.05	-0.05	-0.16	0.18	0.01	0.02	0.04	0.04	–	–	–	–	–	–	–	–	–	–
Net Income	-1.21	-1.15	-5.98	-1.14	-1.54	-1.78	-2.40	-2.04	-1.69	-1.72	-5.79	-3.59	-1.27	-1.34	-1.35	-1.81	-2.42	-1.48
Preferred Dividends	–	–	0	22	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	–	–	-5.98	-23	–	–	-2.40	-2.04	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.03	-0.03	-0.15	-1.18	-0.09	-0.11	-0.14	-0.14	-0.11	-0.15	-0.23	-0.35	-0.13	-0.13	-0.06	-0.19	-0.25	–
EPS (Diluted)(per share)	-0.03	-0.03	-0.15	-1.18	-0.09	-0.11	-0.14	-0.14	-0.11	-0.15	-0.23	-0.35	-0.13	-0.13	-0.06	-0.19	-0.25	–
Shares Outstanding (Basic, Weighted)(shares)	42	42	41	19	17	17	17	15	15	15	25	10	9.98	13	23	9.88	9.82	–
Shares Outstanding (Diluted, Weighted)(shares)	42	42	41	19	17	17	17	15	15	15	25	10	9.98	13	23	9.88	9.82	–
Net Interest Income	0.04	0.04	0.05	0.02	0.01	0.02	0.04	0.04	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -165.9%

Financial strength

Current ratio: 200.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 8841.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.31
Dividend yield: –